Suggestions will update as you type

Weight Management in T2D

Addressing excess weight should be a central focus for T2D management1

an zoomed in icon of an obese male patient looking sad

Diet and lifestyle are key to addressing excess weight, however, pharmacotherapy should also be considered to help people living with diabetes achieve their health goals1

When choosing glucose-lowering therapies for a patient with excess weight, like Rahul, consider a regimen with high to very high glucose lowering and weight loss efficacy; this may include:

Exercise icon

Moderate Exercise1

Nutrition icon

Nutritional Changes1

Sleep icon

Consistent Sleep Patterns1

Medication icon

Medication for Weight Management (as an adjunct to behavioral changes)1

The ADA-EASD Consensus Report recommends medications for glycemic control and weight management as adjuncts to lifestyle intervention1

When choosing glucose-lowering therapies, consider a regimen with high to very high glucose and weight efficacy1

Quote icon

ADA-EASD consensus report1:

“Weight loss of 5%-10% confers metabolic improvement; weight loss of >15%2-5 or more can have a disease-modifying effect and lead to remission of diabetes.”

  1. Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753-2786. doi:10.2337/dci22-0034

  2. Garvey WT. New horizons. A new paradigm for treating to target with second-generation obesity medications. J Clin Endocrinol Metab. 2022;107(4):e1339-e1347. doi:10.1210/clinem/dgab848

  3. Cefalu WT, Bray GA, Home PD, et al. Advances in the science, treatment, and prevention of the disease of obesity: reflections from a diabetes care editors’ expert forum. Diabetes Care. 2015;38(8):1567-1582. doi:10.2337/dc15-1081

  4. Horn DB, Almandoz JP, Look M. What is clinically relevant weight loss for your patients and how can it be achieved? A narrative review. Postgrad Med. 2022;134(4):359-375. doi:10.1080/00325481.2022.2051366

  5. Ryan DH, Yockey SR. Weight loss and improvement in comorbidity: differences at 5%, 10%, 15%, and over. Curr Obes Rep. 2017;6(2):187-194. doi:10.1007/s13679-017-0262-y